Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 6/20 | 0.37 |
| ▸ | PPARD | Q03181 | 6/20 | 0.37 |
| ▸ | PPARA | Q07869 | 6/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389884 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL14728237 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL17418301 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL19382679 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL16908570 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL2944700 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL22445118 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL22445105 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL21087133 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 | |
| SCHEMBL29649576 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRFFAR3HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4525925-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4370157-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023225320-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023288033-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| EP-4087584-A2 | CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| WO-2020190760-A1 | IMMUNOCONJUGATES TARGETING CEA | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020190734-A1 | IMMUNOCONJUGATES TARGETING PD-L1 | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020190762-A1 | MACROMOLECULE-SUPPORTED TLR AGONISTS | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020190731-A1 | IMMUNOCONJUGATES TARGETING HER2 | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-8889657-B2 | Nanoparticle PEG modification with H-phosphonates | MALLINCKRODT LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889657-B2 | Nanoparticle PEG modification with H-phosphonates | MALLINCKRODT LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130066086-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | MALLINCKRODT LLC (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130066086-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | MALLINCKRODT LLC (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066086-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | PHOSPHO1, PHPT1, HPSE | ALDH1A1 3478/4885TSHR 1956/4885FFAR3 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.